Obinutuzumab: all 213 studies that test it
Page 3 of 3. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.
- A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.CompletedNCT02417285Phase 1
- Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)CompletedNCT02401503Phase 2
- Lenalidomide and Obinutuzumab for Previously Untreated CLLWithdrawnNCT02371590Phase 2
- Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL PatientsCompletedNCT02345863Phase 2
- CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding PatientsStatus unknownNCT02320383Phase 2
- Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLCompletedNCT02296918Phase 1
- Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)TerminatedNCT02292225Phase 1
- A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaCompletedNCT02220842Phase 1
- TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02100852Phase 1
- A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic LeukemiaCompletedNCT01685892Phase 1
- A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01671904Phase 1
- GA In NEwly Diagnosed Diffuse Large B Cell LymphomaTerminatedNCT01659099Phase 3
- Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell LymphomaCompletedNCT01582776Phase 1/2